PRFX (PainReform Limited) Volume dana dhuwit perusahaan

Logo grafis painreform.com (PRFX)

PainReform Ltd. (PRFX) lacks direct sales and pricing power due to the current clinical testing stage of its anesthesia formulas. Meanwhile, the modification of known molecules streamlines R&D, while the low-cost production of liquid forms under patent protection enhances operating leverage. The size of the cash reserve demonstrates a level of financial autonomy, with the latest figure standing at 0.00. The stability of future flows now depends exclusively on regulatory approval.

PRFX - Total volume dana dhuwit perusahaan PainReform Limited ing rentang 04.07.2022 - 21.11.2026

Rincian metrik keuangan lan pasar PainReform Ltd (PRFX)

- nilai saham lan prakiraan konsensus rega:
Analisis fundamental perusahaan:PainReform Ltd. PRFX
Produk mawa merek PainReform

This metric reflects the share of liquid reserves relative to market capitalization, determining the asset's actual protection. Analyzing this proportion helps investors assess the risk of cash flow gaps or capital management inefficiencies. The cash volume trend on the chart visualizes the company's current financial stability. For PainReform Ltd. (PRFX), a sufficient cash reserve is critical when implementing innovations in non-opioid pain management. Liquidity ensures the development of extended-release drug technologies.

Pesaing langsung

Dana dhuwit perusahaan Haleon (HLN)|Volume dana dhuwit perusahaan Kenvue Inc. (KVUE)|Volume dana dhuwit perusahaan VRNA (veronapharma.com)|Sisa dhuwit perusahaan MENS|LGND: Dhuwit awis perusahaan|Sisa dhuwit perusahaan AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Dhuwit awis perusahaan|Alvotech - Sisa dhuwit perusahaan|Dhuwit awis perusahaan LQDA|Galapagos Genomics (GLPG) - Aset likuid perusahaan|Volume dana dhuwit perusahaan ANIP|Dhuwit awis perusahaan Afrezza MNKD|Dana dhuwit perusahaan Amphastar AMPH|Aset likuid perusahaan Pacira BioSciences (PCRX)|ARS Corp - Volume dana dhuwit perusahaan|TBPH: Dana dhuwit perusahaan|AQST: Volume dana dhuwit perusahaan|SCPH - Aset likuid perusahaan|TECX (Tectonic) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Tonix Pharmaceuticals Holding Corp. TNXP|Dana dhuwit perusahaan SXT Pharmaceuticals (SXTC)|Volume dana dhuwit perusahaan Eupraxia Pharmaceuticals Inc. (EPRX)|Dana dhuwit perusahaan BioHarvest Sciences BHST|EXOZ (Invizyne) - Total volume dana dhuwit perusahaan|ORMP: Dhuwit awis perusahaan|ENTX (Entera Bio Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|HYFT: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan ABVC BioPharma Inc.|CPIX (cumberlandpharma.com) - Volume dana dhuwit perusahaan|Dana dhuwit perusahaan QNTM|Volume dana dhuwit perusahaan FGEN|Dhuwit awis perusahaan Telomir Pharmaceuticals TELO|Volume dana dhuwit perusahaan RANI (ranitherapeutics.com)|SNYR (Synergy CHC Corporation) - Total volume dana dhuwit perusahaan|RLYB - Dana dhuwit perusahaan|LEXX (Lexaria Bioscience Corp.) - Dhuwit awis lan setara dhuwit awis perusahaan|pulmatrix.com (PULM) - Dana dhuwit perusahaan|PTHL (Pheton) - Dana dhuwit perusahaan|Dana dhuwit perusahaan Aptorum|Cadangan dhuwit perusahaan Lyra Therapeutics Inc. LYRA|Volume dana dhuwit perusahaan IBO|TNFA (TNF Pharmaceuticals, Inc.) - Sisa dhuwit perusahaan|Dana dhuwit perusahaan cbdMD, Inc. YCBD|CYTO (Auris Medical) - Total volume dana dhuwit perusahaan|LIPO - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OPTN (OptiNose)|PIRS: Volume dana dhuwit perusahaan|Procaps Group S.A. (PROC) - Volume dana dhuwit perusahaan|PTPI (Petros Pharma) - Volume dana dhuwit perusahaan|QLI: Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan SLRN|TFFP (TFF Pharmaceuticals Inc.) - Sisa dhuwit perusahaan